Hepatitis B and C Public Policy Association asbl
In April 2009 a group of leading European scientists, professors, public health experts and patient advocates created the Hepatitis B and C Summit Conferences Association as a Luxembourg-based not-for-profit Association (association sans but lucratif). The Association aimed primarily to deliver a summit conference on Hepatitis B and C in Europe, which was held in Brussels in October 2010 under the auspices of the Belgian EU Presidency.
The Association acknowledges with grateful thanks the support of the European Association for the Study of the Liver (EASL), the European Centre for Disease Prevention and Control (ECDC), the European Commission’s Directorate-General for Health and Consumers (DG SANCO), the European Monitoring Centre for Drugs and Drug Addiction (EMDCCA), the European Liver Patients Association (ELPA), the Viral Hepatitis Prevention Board (VHPB), the World Health Organisation – Europe (WHO-Europe) and the World Hepatitis Alliance (WHA) in its past activity.
The Association’s work in the field of viral hepatitis B and C will continue to be developed in collaboration with these stakeholders.
In June 2011 the Association’s name was changed to Hepatitis B and C Public Policy Association to reflect the broader, continuing activities of the Association (see Activities).
Financial contributions received in support of the Association’s activities are made directly to the Association’s Luxembourg bank account, and are disbursed at the discretion of its Directors. The auditors to the Association are Grant Thornton Lux Audit S.A., 83 Pafebruch, L-9308 Capellen, Luxembourg.
The Directors and members of the Association ensure and uphold its independence from its sponsors and other external partners.
Meet The Directors & Members of the Association
Professor of Epidemiology and Preventive Medicine Head, National Retrovirus Reference Centre Director, Department of Hygiene, Epidemiology & Medical Statistics Athens University Medical School, Greece
Liver Unit, Department of Internal Medicine, Vall d’Hebron University Hospital, Barcelona, Spain.
Prof. Maria Buti
Liver Unit, Department of Internal Medicine, Vall d’Hebron University Hospital, Barcelona, Spain
Executive Director, International Centre for Migration and Health (ICMH), Geneva, Switzerland
Chairman, 1st Division of Gastroenterology Fondazione IRCCS Maggiore Hospital Policlinico, Mangiagalli e Regina Elena University of Milan, Italy
Director, Gastroenterology and Internal Medicine University of Palermo, Italy
Prof. Gamal Esmat
Director, Viral Hepatitis Treatment Centers. Ministry of Health. Egypt Vice President, Graduate Studies and Research, Cairo University. Professor, Tropical Medicine and Hepatology, Cairo University Medical School, Egypt
Dr. David Goldberg
Health Protection Scotland Centre for Virus Research Glasgow, Scotland
Head, UHN Liver Clinic, Toronto Western Hospital, Canada
Vice President, European Liver Patients Association (ELPA), Brussels, Belgium
Service d’Hépatologie, Hôpital Beaujon, APHP University of Paris, France
Athens University Medical School Hippokration General Hospital, Athens, Greece
Department of Gastroenterology and Hepatology, Medical University Vienna, Austria.
Professor of Hepatology Imperial College, London, UK
Prof. Nurdan Tozun
Vice Rector, Acibadem University Acibadem Kozyatagi Hospital Dept of Gastroenterology Istanbul, Turkey.
Viral Hepatitis Prevention Board (VHPB) Vaccine and Infectious Disease Institute, Antwerp, Belgium
Research Group Leader, Department of Gastroenterology, Hepatology and Endocrinology Hannover Medical School, Germany.